{"paper_id":"a2fd5529-0d5c-475e-932a-499e455875c0","body_text":"Abstract\nMR-guided high intensity focused ultrasound (MRg HIFU) is a novel method of tissue ablation that incorporates high energy focused ultrasound for tissue heating and necrosis within an MR scanner that provides simultaneous stereotactic tissue targeting and thermometry. To date, MRg HIFU has been used primarily to treat uterine fibroids, but many additional applications in the pelvis are in development. This article reviews the basic technology of MRg HIFU, and the use of MRg HIFU to treat uterine fibroids, adenomyosis, and prostate cancer.\nSimilar content being viewed by others\nReferences\nDobrotwir A, Pun E (2012) Clinical 24 month experience of the first MRgFUS unit for treatment of uterine fibroids in Australia. J Med Imaging Radiat Oncol 56:409–416\nLindstrom PA (1954) Prefrontal ultrasonic irradiation: a substitute for lobotomy. AMA Arch Neurol Psychiatry 72:399–425\nRen XL, Zhou XD, Yan RL, et al. (2009) Sonographically guided extracorporeal ablation of uterine fibroids with high-intensity focused ultrasound: midterm results. J Ultrasound Med 28:100–103\nTsakiris P, Thüroff S, de la Rosette J, Chaussy C (2008) Transrectal high-intensity focused ultrasound devices: a critical appraisal of the available evidence. J Endourol 22:221–229\nOkolo S (2008) Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 22:571–588\nMarshall LM, Spiegelman D, Barbieri RL, et al. (1997) Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 90:967–973\nJacoby VL, Autry A, Jacobson G, et al. (2009) Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches. Obstet Gynecol 114:1041–1048\nhttp://www.alternativesurgeryblog.com/sexual-dysfunction-with-hysterectomy/. Accessed 28 Jan 2013\nMokate T, Wright C, Mander T (2006) Hysterectomy and sexual function. Menopause Int 12:153–157\nAltman D, Granath F, Cnattingius S, Falconer C (2007) Hysterectomy and risk of stress-urinary-incontinence surgery: nationwide cohort study. Lancet 370:1494–1499\nWalker WJ, Pelage JP (2002) Uterine artery embolisation for symptomatic fibroids: clinical results in 400 women with imaging follow up. BJOG 109:1262–1272\nHarding G, Coyne KS, Thompson CL, Spies JB (2008) The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Health Qual Life Outcomes 6:99\nStewart EA, Gostout B, Rabinovici J, et al. (2007) Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol 110:279–287\nWyatt KM, Dimmock PW, Walker TJ, O’Brien PM (2001) Determination of total menstrual blood loss. Fertil Steril 76:125–131\nhttp://www.accessdata.fda.gov/cdrh_docs/pdf4/P040003b.pdf. Accessed 28 Jan 2013\nhttp://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=20708. Accessed 28 Jan 2013\nPistofidis G, Makrakis E, Balinakos P, et al. (2012) Report of 7 uterine rupture cases after laparoscopic myomectomy: update of the literature. J Minim Invasive Gynecol 19:762–767\nPitter MC, Gargiulo AR, Bonaventura LM, Lehman JS, Srouji SS (2013) Pregnancy outcomes following robot-assisted myomectomy. Hum Reprod 28:99–108\nRabinovici J, David M, Fukunishi H, et al. (2010) Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril 93:199–209\nhttp://www.clinicaltrials.gov/ct2/show/NCT00730886. Accessed 28 Jan 2013\nLénárd ZM, McDannold NJ, Fennessy FM, et al. (2008) Uterine leiomyomas: MR imaging-guided focused ultrasound surgery–imaging predictors of success. Radiology 249:187–194\ndeSouza NM, Williams AD (2002) Uterine arterial embolization for leiomyomas: perfusion and volume changes at MR imaging and relation to clinical outcome. Radiology 222:367–374\nStewart EA, Rabinovici J, Tempany CM, et al. (2006) Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 85:22–29\nJudson O (2010) Enhancing the placebo. Op-Ed column. New York Times, May 4, 2010. http://www.nytimes.com/2010/05/04/opinion/04judson.html. Accessed 5 March 2011\nSanket D, Bero L, Redberg R, et al. (2009) Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA 302:2679–2685\nhttp://clinicaltrials.gov/ct2/show/NCT00656305?term=mrgfus&rank=7. Accessed 5 March 2011\nBodenheimer T (2000) Uneasy alliance–clinical investigators and the pharmaceutical industry. N Engl J Med 342:1539–1544\nAngell M (2008) Industry-sponsored clinical research: a broken system. JAMA 300:1069–1071\nSteinbrook R (2009) Controlling conflict of interest—proposals from the institute of medicine. N Engl J Med 360:2160–2163\nJacoby V, Jacoby A, Kohi M, et al. (2012) MR guided focused ultrasound for uterine fibroids: a pilot randomized placebo controlled trial. In: Current and future applications of focused ultrasound 2012, 3rd International Symposium, Program Book. p 44\nYoo EH, Lee PI, Huh CY, et al. (2007) Predictors of leiomyoma recurrence after laparoscopic myomectomy. J Minim Invasive Gynecol 14:690–697\nHanafi M (2005) Predictors of leiomyoma recurrence after myomectomy. Obstet Gynecol 105:877–881\nFunaki K, Fukunishi H, Sawada K (2009) Clinical outcomes of magnetic resonance-guided focused ultrasound surgery for uterine myomas: 24-month follow-up. Ultrasound Obstet Gynecol 34:584–589\nSpies J, Bruno J, Czeyda-Pommersheim F, et al. (2005) Long-term outcome of uterine artery embolization of leiomyomas. Obstet Gynecol 106:933–939\nKatsumori T, Kasahara T, Akazawa K (2006) Long-term outcomes of uterine artery embolization using gelatin sponge particles alone for symptomatic fibroids. AJR Am J Roentgenol 186:848–854\nRuuskanen A, Sipola P, Hippeläinen M, Wüstefeld M, Manninen H (2009) Pain after uterine fibroid embolisation is associated with the severity of myometrial ischaemia on magnetic resonance imaging. Eur Radiol 19:2977–2985\nKim KA, Yoon SW, Yoon BS, et al. (2011) Spontaneous vaginal expulsion of uterine myoma after magnetic resonance-guided focused ultrasound surgery. J Minim Invasive Gynecol 18:131–134\nRadeleff B, Eiers M, Bellemann N, et al. (2010) Expulsion of dominant submucosal fibroids after uterine artery embolization. Eur J Radiol 75:e57–e63\nhttp://lawmedconsultant.com/385/recent-large-malpractice-verdicts/. Accessed 28 Jan 2013\nCockerham AZ (2012) Adenomyosis: a challenge in clinical gynecology. J Midwifery Womens Health 57:212–220\nVercellini P, Vigano P, Somigliana E, et al. (2006) Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynecol 20:465–477\nFan TY, Zhang L, Chen W, et al. (2012) Feasibility of MRI-guided high intensity focused ultrasound treatment for adenomyosis. Eur J Radiol 81:3624–3630\nFukunishi H, Funaki K, Yamaguchi K, Sawada K (2011) Two-year outcome of MRgFUS treatment of adenomyosis. Poster at 21st World Congress of the International Society of Ultrasound in Obstetrics and Gynecology, 2011\nKim MD, Kim S, Kim NK, et al. (2007) Long-term results of uterine artery embolization for symptomatic adenomyosis. AJR Am J Roentgenol 188:176–181\nStamey TA, McNeal JE (1992) Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds) Campbell’s urology, vol. 2, 6th edn. Philadelphia: WB Saunders, pp 1159–1221\nEpstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374\nCarter HB, Sauvageot J, Walsh PC, Epstein JI (1997) Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 157:2206–2209\nEggener SE, Mueller A, Berglund RK, et al. (2013) A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 189(1 Suppl):S19–S25\nAhmed HU, Moore C, Emberton M (2009) Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol 18:219–232\nMarberger M, Carroll PR, Zelefsky MJ, et al. (2008) New treatments for localized prostate cancer. Urology 72(6 Suppl):S36–S43\nPolascik TJ, Mouraviev V (2008) Focal therapy for prostate cancer. Curr Opin Urol 18:269–274\nShelley M, Wilt TJ, Coles B, Mason MD (2007) Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 18:CD005010\nBarqawi AB, Crawford ED (2007) The current use and future trends of focal surgical therapy in the management of localized prostate cancer. Cancer J 13:313–317\nMuto S, Yoshii T, Saito K, et al. (2008) Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 38:192–199\nAhmed HU, Emberton M (2008) Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? World J Urol 26:457–467\nMiller DC, Sanda MG, Dunn RL, et al. (2005) Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23:2772–2780\nBarocas DA, Cowan JE, Smith JAJr, Carroll PR, CaPSURE Investigators (2008) What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 180:1330–1334\nSchröder FH, Hugosson J, Roobol MJ, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328\nAndriole GL, Crawford ED, Grubb RL III, et al. (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310–1319\nSanghvi NT, Foster RS, Bihrle R, et al. (1999) Noninvasive surgery of prostate tissue by high intensity focused ultrasound: an updated report. Eur J Ultrasound 9:19–29\nLee HM, Hong JH, Choi HY (2006) High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 9:439–443\nBlana A, Walter B, Rogenhofer S, Wieland WF (2004) High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 63:297–300\nVallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F (2004) Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 171(6 Pt 1):2265–2267\nFicarra V, Antoniolli SZ, Novara G, et al. (2006) Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 98:1193–1198\nHan KR, Cohen JK, Miller RJ, et al. (2003) Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 170(4 Pt 1):1126–1130\nMouraviev V, Mayes JM, Polascik TJ (2009) Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 6:205–215\nJayram G, Eggener SE (2009) Patient selection for focal therapy of localized prostate cancer. Curr Opin Urol 19:268–273\nScheidler J, Hricak H, Vigneron DB, et al. (1999) Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging–clinicopathologic study. Radiology 213:473–480\nYu KK, Scheidler J, Hricak H, et al. (1999) Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213:481–488\nCoakley FV, Kurhanewicz J, Lu Y, et al. (2002) Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223:91–97\nChang S, Westphalen A, Jha P, et al. (2011) Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focused ultrasound surgery-preliminary experience. American Roentgen Ray Society Annual Program. p 33\nAnwar MM, Westphalen AC, Jung A, et al. (2012) Role of endorectal MRI and MRSI in defining the dominant intraprostatic lesion in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. Int J Radiat Oncol Biol Phys 84:S403\nYerram N, Hoang A, Partanen A, et al. (2012) MR-guided trans-urethral prostate HIFU in a preclinical model. Mid Atlantic Section of the American Urological Association 2012 Annual Meeting Abstract. http://meeting.maaua.org/abstracts/2012/MP24.cgi. Accessed 11 April 2013\nKinsey AM, Diederich CJ, Rieke V, et al. (2008) Transurethral ultrasound applicators with dynamic multi-sector control for prostate thermal therapy: in vivo evaluation under MR guidance. Med Phys 35:2081–2093\nZini C, Hipp E, Thomas S, et al. (2012) Ultrasound- and MR-guided focused ultrasound surgery for prostate cancer. World J Radiol 4:247–252\nFalk MH, Issels RD (2001) Hyperthermia in oncology. Int J Hyperthermia 17:1–18\nMukhopadhaya A, Mendecki J, Dong X, et al. (2007) Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res 67:7798–7806\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nCoakley, F.V., Foster, B.R., Farsad, K. et al. Pelvic applications of MR-guided high intensity focused ultrasound. Abdom Imaging 38, 1120–1129 (2013). https://doi.org/10.1007/s00261-013-9999-2\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00261-013-9999-2","source_license":"CC0","license_restricted":false}